Who Owns McKesson Medical-Surgical?

What does McKesson do?
McKesson distributes pharmaceutical products, including brand-name drugs, generic drugs, and specialty medications, to pharmacies, hospitals, physician offices, and other healthcare providers across the United States and Canada. The company also operates the US Oncology Network, distributes medical-surgical supplies, and provides technology solutions to biopharma manufacturers through its Prescription Technology Solutions segment.

Is McKesson publicly traded?
Yes, McKesson Corporation trades on the New York Stock Exchange under ticker symbol MCK. The company has no controlling shareholder, with ownership distributed among institutional investors including Vanguard Group and BlackRock.

What is McKesson's annual revenue?
In fiscal year 2024 (ended March 31, 2024), McKesson reported revenue of approximately $308.9 billion, a 10% increase from the prior fiscal year. The U.S. Pharmaceutical segment accounted for approximately $275 billion of total revenue.

Who is McKesson's CEO?
Brian Tyler has served as Chief Executive Officer of McKesson since April 2019, succeeding John Hammergren. Tyler has led the company's strategic focus on oncology and biopharma services as higher-growth businesses within the healthcare distribution ecosystem.

When was McKesson founded?
McKesson was founded in 1833 by John McKesson and Charles Olcott in New York City as Olcott & McKesson, making it one of the oldest continuously operating companies in the United States.

What is McKesson's role in the opioid settlement?
McKesson, along with Cencora and Cardinal Health, reached a $21 billion settlement with U.S. states and local governments in 2022 to resolve claims that the three distributors failed to adequately monitor suspicious opioid orders. McKesson's share of the settlement is approximately $7.9 billion, to be paid over 18 years.